2021
DOI: 10.3389/fimmu.2021.785457
|View full text |Cite
|
Sign up to set email alerts
|

Role of CXCL5 in Regulating Chemotaxis of Innate and Adaptive Leukocytes in Infected Lungs Upon Pulmonary Influenza Infection

Abstract: Respirovirus such as influenza virus infection induces pulmonary anti-viral immune response, orchestration of innate and adaptive immunity restrain viral infection, otherwise causes severe diseases such as pneumonia. Chemokines regulate leukocyte recruitment to the inflammation site. One chemokine CXCL5, plays a scavenging role to regulate pulmonary host defense against bacterial infection, but its role in pulmonary influenza virus infection is underdetermined. Here, using an influenza (H1N1) infected CXCL5-/-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
13
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 23 publications
(13 citation statements)
references
References 40 publications
0
13
0
Order By: Relevance
“…37 ENA-78 is primarily a neutrophil chemoattractant, and counterintuitively, the expression of ENA-78 was higher in children infected with RV. 38 In the convalescence phase, the former differences observed in the acute phase were dissipated. However, in the convalescence phase (2 weeks later) the RV-HBoV1 group was demonstrated by decreased expression of fractalkine, MCP-3, and IL-8 when compared with the RV group.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…37 ENA-78 is primarily a neutrophil chemoattractant, and counterintuitively, the expression of ENA-78 was higher in children infected with RV. 38 In the convalescence phase, the former differences observed in the acute phase were dissipated. However, in the convalescence phase (2 weeks later) the RV-HBoV1 group was demonstrated by decreased expression of fractalkine, MCP-3, and IL-8 when compared with the RV group.…”
Section: Discussionmentioning
confidence: 99%
“…TARC distinguishes itself by selectively binding to C‐C chemokine receptor type 4, thereby resulting in induction the of type 2 immune responses via, for example, ILC2, Th2 cells, and airway eosinophils 37 . ENA‐78 is primarily a neutrophil chemoattractant, and counterintuitively, the expression of ENA‐78 was higher in children infected with RV 38 …”
Section: Discussionmentioning
confidence: 99%
“…At study entry, children infected with RV were characterized by a higher expression of eotaxin-2 and TARC; the former promotes the migration of eosinophils into the lungs ( 27 ), and the latter selectively binds to CCR4, leading to the activation of a type 2 immune response via , e.g., Th2 cells, ILC2, and airway eosinophils ( 28 ). The expression of ENA-78, although counterintuitive is primarily a neutrophil chemoattractant, was higher in children infected with RV ( 29 ). Children infected with RSV were characterized by a higher activity of proinflammatory-associated cytokines IL-1β and its antagonist IL-1RA.…”
Section: Discussionmentioning
confidence: 99%
“…The CXCL1-3/CXCR2 biological axis is a critical facilitator of lung injury in this setting since neutrophil mobilization and pulmonary injury were reduced upon treatment of mice with anti-CXCR2 neutralizing antibody following prior exposure to dsRNA [ 144 ]. The CXCL5/CXCR2 axis might also be involved in the regulation of leukocyte mobilization after pulmonary influenza infection [ 145 ]. Reparixin, a CXCR2 inhibitor with a promising profile in the treatment of severe COVID-19 pneumonia, has completed a phase 3 clinical trial ( NCT04878055 ) in adult patients with the disease [ 146 ].…”
Section: The Role and Therapeutic Relevance Of CXC Motif Chemokines A...mentioning
confidence: 99%
“…e CXCL5/CXCR2 axis might also be involved in the regulation of leukocyte mobilization after pulmonary influenza infection [145]. Reparixin, a CXCR2 inhibitor with a promising profile in the treatment of severe COVID-19 pneumonia, has completed a phase 3 clinical trial (NCT04878055) in adult patients with the disease [146].…”
Section: Viral Pneumonia and Erapeutic Prospects Of Cxcrsmentioning
confidence: 99%